272 related articles for article (PubMed ID: 20625121)
1. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
[TBL] [Abstract][Full Text] [Related]
2. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
[TBL] [Abstract][Full Text] [Related]
3. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
5. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract][Full Text] [Related]
6. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
7. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
9. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
10. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
Patel M; Ikeda S; Pilat SR; Kurzrock R
JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
13. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
17. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
18. Siltuximab: first global approval.
Markham A; Patel T
Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
[TBL] [Abstract][Full Text] [Related]
19. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
20. Castleman's disease, pathophysiology, advances in diagnosis and treatment.
Pertusa Mataix R; Loaiza Cabello D; García Morillo JS
Med Clin (Barc); 2024 Mar; 162(6):283-290. PubMed ID: 38016855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
